DDX28 Antibody

What is DDX28 and what cellular functions does it regulate?

DDX28 is a DEAD box protein family member that functions as a negative regulator of hypoxia-inducible factor 2α (HIF-2α) in human cells. It appears to be expressed ubiquitously across tissues, with particularly well-characterized functions in glioblastoma cells . DDX28 has been detected in multiple cellular compartments including mitochondria, cytoplasm, and nuclei.

Functionally, DDX28 plays several important roles:

• It negatively regulates HIF-2α and the eIF4E2-mediated translation of oncogenic mRNAs

• When DDX28 protein levels decrease during hypoxia, HIF-2α levels increase

• DDX28 directly interacts with HIF-2α but not with HIF-1α or the m7GTP cap structure

• DDX28 depletion leads to increased association of eIF4E2 with the m7GTP cap structure

• DDX28 is also involved in mitochondrial function, as its silencing impairs mitoribosome assembly and oxidative phosphorylation

These characteristics position DDX28 as a potential tumor suppressor, as its levels are reduced in several cancers, including gliomas, relative to normal tissue .

What applications is the DDX28 antibody validated for in research?

The DDX28 antibody (11617-1-AP) has been validated for several experimental applications:

The antibody has demonstrated reactivity with human, mouse, and rat samples, making it suitable for comparative studies across these species . It has been specifically tested and shown positive detection in:

• Western blot: HEK-293T cells

• Immunohistochemistry: human prostate cancer tissue (with recommended antigen retrieval using TE buffer pH 9.0 or alternatively citrate buffer pH 6.0)

The antibody targets the full DDX28 protein, which has a calculated molecular weight of 60 kDa (540 amino acids) and shows the expected band at this size in Western blot applications .

How does DDX28 function change under hypoxic conditions, and what methodological approaches can detect these changes?

Under hypoxic conditions (1% O₂), DDX28 exhibits important functional changes that researchers should consider when designing experiments:

• Protein level changes: When cells are exposed to hypoxia for 24 hours, DDX28 protein levels decrease while HIF-2α levels increase . This inverse relationship is functionally significant.

• Protein-protein interactions: In hypoxic conditions, DDX28 interacts specifically with HIF-2α but not with HIF-1α or eIF4E2 . This interaction can be detected through co-immunoprecipitation experiments using exogenously tagged proteins (due to limitations in antibody specificity for endogenous detection).

• Effects on translation: DDX28 depletion during hypoxia increases the association of eIF4E2 with the m7GTP cap structure and increases polysome association of eIF4E2 target mRNAs, including EGFR, IGF1R, and EPAS1 (HIF-2α) .

Methodological approaches to study these changes include:

• Western blotting to quantify DDX28 and HIF-2α protein levels in hypoxia vs. normoxia

• Co-immunoprecipitation with GFP-tagged HIF-2α to detect interaction with DDX28

• Subcellular fractionation to measure cytoplasmic vs. nuclear levels of HIF-2α

• Polysome fractionation to measure translation efficiency of target mRNAs

• qRT-PCR on monosome and polysome fractions to assess translation status of specific transcripts

What are the key technical considerations when using DDX28 antibody for detecting subcellular localization changes?

When studying DDX28's subcellular localization or its effects on HIF-2α localization, researchers should consider these technical aspects:

• Subcellular fractionation quality: Effective separation of cytoplasmic and nuclear fractions is critical. Studies have shown that DDX28 depletion increases both cytoplasmic and nuclear HIF-2α levels in hypoxic conditions .

• Antibody specificity concerns: The available research indicates limitations in antibody specificity for detecting endogenous DDX28 , which is why exogenously tagged proteins are often used in co-immunoprecipitation experiments. When using the commercial antibody (11617-1-AP), researchers should include appropriate controls to validate specificity in their experimental system.

• Fixation and antigen retrieval for IHC/ICC: For immunohistochemistry applications, the manufacturer recommends antigen retrieval with TE buffer pH 9.0, or alternatively with citrate buffer pH 6.0 . This step is crucial for optimal detection.

• Storage and handling: The antibody should be stored at -20°C in aliquots containing PBS with 0.02% sodium azide and 50% glycerol (pH 7.3) . Proper storage ensures antibody stability and consistent results.

• Sample preparation: When studying DDX28's effect on HIF-2α localization, fractionation protocols that maintain protein-protein interactions are essential, as DDX28 directly interacts with HIF-2α .

Why might DDX28 depletion increase HIF-2α protein levels but not its transcriptional activity?

This apparent contradiction in experimental results requires careful methodological consideration:

Several mechanisms might explain this discrepancy:

• Saturation effect: In hypoxic control cells, nuclear HIF-2α may already be abundant enough to saturate available DNA binding sites, so additional HIF-2α doesn't increase transcriptional output .

• Post-translational modifications: The pool of additional HIF-2α resulting from DDX28 depletion may lack necessary post-translational modifications for transcriptional activity.

• Cofactor limitations: Transcriptional activity might be limited by availability of essential cofactors rather than HIF-2α levels.

• Distinct pools of HIF-2α: DDX28 may interact with a specific pool of HIF-2α that is sequestered from transcriptional activity but can be redirected to translational regulation .

To investigate this phenomenon, researchers should consider:

• Chromatin immunoprecipitation (ChIP) assays to assess HIF-2α binding to target promoters

• Analysis of post-translational modifications of HIF-2α

• Co-immunoprecipitation studies to identify differential protein interactions of HIF-2α in DDX28-depleted versus control cells

How do you reconcile DDX28's mitochondrial functions with its role in HIF-2α regulation?

DDX28 has been identified as having both mitochondrial functions and a role in HIF-2α regulation, which presents an interesting experimental challenge:

DDX28 has been detected in mitochondria, cytoplasm, and nuclei . Its known mitochondrial functions include roles in mitoribosome assembly, with RNAi-mediated silencing of DDX28 impairing mitoribosome assembly and oxidative phosphorylation . Since mitochondrial dysfunction can potentially affect HIF-α levels through increased reactive oxygen species (ROS), this raises questions about whether DDX28's effect on HIF-2α is direct or mediated through its mitochondrial functions.

Research addressing this question has shown:

• DDX28 depletion in hypoxic cells did not produce significant changes to mitochondrial fusion, morphology, or membrane potential compared to control cells .

• There were no significant changes in mRNA abundances of genes encoding antioxidant proteins (including Cu/Zn-superoxide dismutase, NAD(P)H:quinone oxidoreductase, sulfiredoxin-1, and thioredoxin reductase 1) between hypoxic DDX28-depleted cells and control cells .

• Direct interaction between DDX28 and HIF-2α was demonstrated through co-immunoprecipitation .

These findings suggest that DDX28's effect on HIF-2α regulation is independent of its mitochondrial functions. Researchers investigating this relationship should include proper controls for mitochondrial function and ROS levels in their experimental design.

What are the optimal conditions for using DDX28 antibody in Western blot applications?

For optimal Western blot results with the DDX28 antibody (11617-1-AP), researchers should follow these protocol recommendations:

• Sample preparation:

  • Use freshly prepared lysates when possible

  • Include protease inhibitors in lysis buffer to prevent degradation

  • The antibody has been validated in human (HEK-293T), mouse, and rat samples

• Antibody dilution:

  • Recommended dilution range: 1:500-1:1000

  • Optimal dilution may be sample-dependent and should be determined empirically

• Detection considerations:

  • Expected molecular weight: 60 kDa

  • Include positive control (e.g., HEK-293T cell lysate) when first optimizing

  • Consider using gradient gels (4-12%) for better resolution

• Blocking and washing:

  • Follow the manufacturer's provided protocol for DDX28 antibody (11617-1-AP)

  • BSA-based blocking solutions may provide better results than milk for phospho-protein detection if studying DDX28 modifications

• Special considerations for hypoxia experiments:

  • When comparing normoxic and hypoxic samples, DDX28 levels decrease under hypoxia (1% O₂, 24 hours), which should be considered when loading controls and interpreting results

What experimental approaches can reliably assess the functional impact of DDX28 in cancer models?

Based on DDX28's identified roles as a potential tumor suppressor and regulator of HIF-2α-mediated translation, several experimental approaches can assess its functional impact in cancer models:

• Cell proliferation and viability assays:

  • DDX28 depletion has been shown to confer a proliferative advantage to hypoxic (but not normoxic) cells

  • Methods: Crystal violet staining to monitor viable cells over 72 hours at 24-hour intervals and bromodeoxyuridine (BrdU) incorporation to measure actively dividing cells

  • Compare proliferation rates in normoxia versus hypoxia (1% O₂) conditions

• Translation efficiency measurements:

  • Polysome fractionation to assess association of eIF4E2 with ribosomes

  • qRT-PCR on monosome and polysome fractions to measure DDX28-dependent translation of target mRNAs like EGFR, IGF1R, and EPAS1 (HIF-2α)

• Protein-protein interaction studies:

  • Co-immunoprecipitation to assess DDX28 interaction with HIF-2α

  • RNA interference (RNAi) to deplete DDX28 and measure changes in HIF-2α levels and activity

  • Subcellular fractionation to measure cytoplasmic versus nuclear HIF-2α levels

• In vivo models:

  • Xenograft studies using DDX28-depleted cancer cells to assess tumor growth rates

  • Immunohistochemistry of patient samples to correlate DDX28 levels with clinical outcomes (the commercial antibody 11617-1-AP has been validated for IHC in human prostate cancer tissue)

When designing these experiments, researchers should use at least two independent shRNA sequences targeting DDX28 to control for off-target effects, and include appropriate controls for both normoxic and hypoxic conditions .

How might DDX28 antibodies be used to investigate the relationship between hypoxia response and cancer progression?

DDX28 antibodies provide a valuable tool for investigating the critical relationship between hypoxia response and cancer progression:

• Biomarker potential in tissue analysis:

  • DDX28 protein levels are reduced in several cancers, including gliomas, compared to normal tissue

  • Researchers can use DDX28 antibodies for IHC analysis of patient tissue microarrays to correlate DDX28 expression with:

    • Tumor grade and stage

    • HIF-2α expression

    • Patient outcome and treatment response

    • Hypoxic regions within tumors (via co-staining with hypoxia markers)

• Mechanistic studies of translational regulation:

  • DDX28 depletion increases translation of oncogenic mRNAs controlled by eIF4E2/HIF-2α, including EGFR and IGF1R

  • Researchers can use DDX28 antibodies to:

    • Immunoprecipitate DDX28-containing complexes for RNA-seq to identify additional target mRNAs

    • Investigate changes in translational landscape under various oxygen conditions

    • Study coordination between transcriptional and translational hypoxia responses

• Therapeutic resistance investigations:

  • Since hypoxia contributes to therapy resistance, DDX28's role in modulating HIF-2α makes it relevant to treatment response

  • Experimental approaches:

    • Combine DDX28 expression analysis with drug sensitivity assays

    • Compare DDX28 levels before and after treatment failure

    • Assess whether DDX28 depletion affects sensitivity to HIF-2α inhibitors

• Cell-specific responses:

  • While research has focused on U87MG glioblastoma cells, DDX28 is expressed ubiquitously and may function similarly in other tissues

  • Use DDX28 antibodies to compare expression and function across multiple cancer types and correlate with hypoxia response profiles

What are the technical challenges in using DDX28 antibody for multiplex immunofluorescence with other hypoxia markers?

Multiplex immunofluorescence combining DDX28 antibody with other hypoxia markers presents several technical challenges that researchers should address:

• Antibody species compatibility:

  • The commercial DDX28 antibody (11617-1-AP) is a rabbit polyclonal

  • When multiplexing, select secondary antibodies or detection systems that avoid cross-reactivity

  • Consider using directly conjugated primary antibodies for more complex panels

• Signal intensity balancing:

  • DDX28 levels decrease during hypoxia while HIF-2α increases

  • These opposing expression patterns require careful exposure optimization

  • Consider sequential detection methods if signal intensities differ dramatically

• Subcellular localization differences:

  • DDX28 has been detected in mitochondria, cytoplasm, and nuclei

  • HIF-2α accumulates in both cytoplasm and nucleus under hypoxia and more so when DDX28 is depleted

  • High-resolution imaging (confocal or super-resolution) may be necessary to precisely determine co-localization

• Antigen retrieval optimization:

  • The manufacturer recommends TE buffer pH 9.0 for DDX28 antibody (11617-1-AP)

  • This may not be optimal for all hypoxia markers in a multiplex panel

  • Test compatibility of different retrieval methods with all antibodies in the panel

• Tissue-specific considerations:

  • Hypoxic regions in tissues often show necrotic areas and altered morphology

  • Careful selection of regions of interest and inclusion of appropriate tissue controls are essential

  • Consider automated segmentation methods for objective quantification

• Protocol recommendations:

  • Start with sequential single staining to establish optimal conditions for each antibody

  • Progress to dual staining before attempting more complex panels

  • Include single-stained controls for spectral unmixing if using confocal systems with spectral detection